Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals (HEMO.L) Interview

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation at the H.C. Wainwright Global Life Sciences Conference. The Company will be featured as a presenting company. The conference will be held on a virtual platform from March 9-10, 2021.As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates.If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link to register for the conference: www.hcwevents.com/globalconference.The conference will feature over 400 corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Global Life Sciences Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases. "https://www.share-talk.com/dr-vladislav-sandler-ceo-co-founder-of-hemogenyx-pharmaceuticals-hemo-l-interview/